RecruitingPhase 1Phase 2NCT05180994

Topical Infliximab in Eyes With Penetrating Keratoplasty

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Enrollment

50 participants

Start Date

May 1, 2022

Study Type

INTERVENTIONAL

Conditions

Glaucoma Following Surgery

Summary

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying No topical infliximab and a drug called Topical infliximab for people with glaucoma following surgery. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTopical infliximab

Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.

OTHERNo topical infliximab

No treatment with infliximab.

Locations(1)

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05180994